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RATIONALE FOR A HOSPITAL-BASED 
PNEUMOCOCCAL VACCINE TRIAL FOR 
HIV-SEROPOSITIVE SOUTH AFRICANS 
In poor countries where affordable therapeutic options 
for human immunodeficiency virus (Hlv> infection are 
extremely limited, the availability of cost-effective pro- 
phylactic measures to prevent opportunistic infection 
becomes vitally important. Bacterial pneumonia, espe- 
cially due to the pneumococcus, is the most frequently 
encountered secondary infection complicating HIV dis- 
ease in the teaching hospitals in Johannesburg and 
Soweto, South Africa.‘a2 Although its effectiveness in HIV- 
infected patients has not been demonstrated in prospec- 
tive clinical trials, a case-control study has demonstrated 
benefit of pneumococcal vaccination in preventing inva- 
sive disease, and vaccine is currently recommended as 
for other high risk hosts.3,4 However, the optimal loca- 
tion for administering pneumococcal vaccination to max- 
imize usefulness is not clear. Hospital-based strategies 
have been recommended for several vaccines, including 
pneumococcal vaccine, to expand vaccine coverage. The 
authors sought to explore the rationale for a pre-dis- 
charge, hospital-based pneumococcal vaccination trial for 
patients with HIV infection in South Africa. 
Culture logbooks of the Pneumococcal Research Unit 
Laboratory of the South African Institute for Medical 
Research (SAIMR) were retrospectively reviewed; they 
identified 104 patients with Streptococcus pneumoniae 
recovered from blood (n = 88 patients), cerebrospinal 
fluid (n = 9), or both (n = 7) during the 1997 calendar 
year. Of these, 94 patients were evaluable according to 
the available inpatient and HIV clinic medical records, and 
HIV enzyme-linked immunosorbent assay (ELISA) antibody 
and CD4+ cell count parameters. Dates of hospitalization 
for the 5 years prior to admission for pneumococcal infec- 
tion as well as time of the frost-positive HIV antibody result 
were retrieved from hospital medical records. No patients 
had received pneumococcal vaccination. 
Seventy patients were 2 years of age or older; 24 
patients were children less than 2 years of age. Where HIV 
antibody status was known, 92% were HIV-seropositive. 
Of the 53 HIV-seropositive persons 2 years of age or 
older, 20 (38%) had been hospitalized at least once dur- 
ing the previous 5 years (53 separate admissions), and a 
vast majority of patients were aware of their HIV status 
before or during the time of previous hospitalization. 
Human immunodeficiency virus antibody status was 
known by these patients before (62%), during (30%), or 
after (8%) hospitalization for pneumococcal disease; for 
children less than 2 years old, these figures were 29%, 
710/o, and O%, respectively. Only 3 (6%) of 53 isolates from 
HIV-seropositive patients 2 years of age or older had 
CD4+ lymphocyte counts known before pneumococcal 
hospitalization, indicating poor HIV clinic enrollment in 
Johannesburg or Soweto. Subtyping of pneumococcal 
strains was not performed on all study isolates. If only 
serotypes (and not subtypes) were considered, up to 96% 
of invasive pneumococcal isolates from patients 2 years 
of age or older belonged to serotypes present in, or cross- 
reactive with the current 23-polyvalent polysaccharide 
pneumococcal vaccine; for children less than 2 years of 
age, 79% of isolates were contained in the 9-valent con- 
jugate vaccine. 
Observers have long identified missed opportunities, 
including hospitalization, where pneumococcal vaccine 
could be administered. In the United States, the Centers 
for Disease Control and Preventive (CDC) recommends 
administration of pneumococcal vaccine to inpatients as 
a strategy for improving vaccine coverage among adults.5 
Previous hospitalization has been shown to be a risk fac- 
tor for subsequent serious pneumococcal infection, and 
modest levels of inpatient vaccination could substantially 
reduce hospital admissions.6 Outpatient clinic-based pneu- 
mococcal immunization seems logical because it offers 
the advantage of identifying asymptomatic HIV-seropos- 
itive persons early in their infection. However, the 
authors’ data indicate that although a majority of patients 
had been HIV antibody-tested prior to their hospitaliza- 
tion for pneumococcal disease, and thus knew their HIV 
status, a small percentage (6%) of these individuals were 
formally enrolled in any HIV clinic, as indicated by infre- 
quent prior CD4+ cell count determinations (HIV clinics 
in Johannesburg and Soweto routinely perform baseline 
and follow-up CD4+ cell counts). Almost 40% of patients, 
however, had been hospitalized at least once, for any rea- 
son, during the preceding 4 years, thereby representing 
instances where pneumococcal vaccine could have been 
administered, to prevent future infection. In-hospital, pre- 
discharge HIV testing and pneumococcal vaccination, 
perhaps combined with outpatient HIV site testing 
vaccination could increase pneumococcal vaccine cov- 
erage among HIV-infected patients in South Africa. Vac- 
cination of hospitalized patients with first-episode 
pneumococcal disease might also have an important role 
in reducing the high rates of second pneumococcal infec- 
tions.’ In light of concern about the efficacy and safety 
of pneumococcal vaccine in HIV-infected Africans,8 its 
use should be evaluated in further clinical trials. 
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FOOD IRRADIATION AND VITAMIN LOSS 
I am writing in response to Dr. Donald B. Louria’s “Coun- 
terpoint on Food Irradiation,” which I think contains some 
misleading statements about food irradiation in the United 
States as well as about the effects of irradiation on the 
nutritional value of foods. 
Dr. Louria expresses great concern about losses of 
vitamins and, possibly, other nutrients as a result of food 
irradiation. No reputable nutritionist would deny that Irma- 
diation can lower the vitamin content of foods. Thiamin 
and vitamin C likely are the most vulnerable, but the 
losses of thiamin as a result of irradiation of beef, for 
example, are less than that which occurs with canning or 
other thermal processing. And vitamin C losses when 
fruits and vegetables are irradiated are “small relative to 
the natural variance in vitamin C content.“’ Pasteuriza- 
tion of milk results in losses of vitamin B,, (lo%>, thiarnin 
(lo%), vitamin C (lo-25%), and folic acid (10%); but the 
national acceptance of milk pasteurization has not 
resulted in widespread deficiencies of these nutrients 
(none of which are added back to milk).2 
Further, Dr. Louria’s letter seems to imply that all 
foods would be irradiated if the process were widely 
accepted, and that consumers would not be informed 
that their foods are irradiated. First, it is unclear that pro- 
ducers have any intention of irradiating all foods. Second, 
it is already required that any irradiated foods on sale in 
retail stores be identified by the green radura symbol- 
a flower in a broken circle. So consumers not only will 
be informed of which foods are irradiated but also will 
have a choice as to whether to buy them. 
Dr. Louria expresses concerns about the approxi- 
mately 16 million older Americans who he says have low 
blood levels of at least one vitamin. Is he not concerned 
about the older Americans who are particularly suscep- 
tible to the adverse effects of food poisoning, or about 
people taking immunosuppressant medications who also 
are more susceptible? 
Currently, most Americans are in very little danger 
of nutrient deficiency. Citing small nutrient losses as a 
consequence of irradiation, or any food processing tech- 
nique, to inveigh against that process denies a huge body 
of scientific literature on the wholesomeness and 
enhanced safety of foods so treated. 
References 
1. Williams AW, Erdman JW Jr. Food processing: nutrition, safety, 
and quality balances. In: Shils ME, Olson JA, Shike M, Ross AC, 
eds. Modern nutrition in health and disease. 9th Ed. Balti- 
more: Williams & Wilkins, 1999. 
2. Swaisgood HE. Characteristics of edible fluids of animal ori- 
gin: milk. In: Fermema OR, ed. Food chemistry. 2nd Ed. New 
York: Marcel Dekker, Inc., 1985. 
Ruth Kava, PhD, RD 
Director of Nutrition 
American Council on Science and Health 
New York, New York 
ARE THERE VALID CONCERNS ABOUT FOOD 
IRRADIATION? 
Dr. Louria’s “Counterpoint on Food Irradiation,” presents 
several questions of the proponents and processors of 
irradiated foods. The following is a response to those 
points. 
Dr. Louria’s first point is that he does not believe that 
Dr. Steele used the current analysis of food-related ill- 
nesses and cites the data of Mead et al.’ However, upon 
closer inspection, I note that Dr. Steele mentions “An esti- 
mated 76,000,000 cases of foodborne infection.. .approx- 
imately 6000 deaths.” Mead estimates 76 million 
